Plasma homovanillic acid as an index of brain dopamine metabolism: enhancement with debrisoquin.
Plasma homovanillic acid as an index of brain dopamine metabolism: enhancement with debrisoquin.
复制标题
血浆高香草酸作为脑多巴胺代谢的指标：用碎片喹啉增强。
DOI：
10.1016/0024-3205(83)90370-3
复制
发表时间：
1983
期刊：
影响因子：
6.1
通讯作者：
Roth,RH
中科院分区：
文献类型：
--
作者：
Sternberg,DE;Heninger,GR;Roth,RH
多巴胺（DA）代谢物同质香草酸（HVA）的血浆水平可能是衡量中枢DA系统产生的脑HVA的有用指标。尽管外周对血浆HVA有显著的影响，但改变脑HVA的实验操作也会产生血浆HVA水平的平行变化。本研究旨在评估血浆HVA反映氟哌啶醇诱导的脑HVA升高的能力是否可以通过减少外周源对血浆HVA的贡献而得到加强。硫酸碎片醌是一种不进入大脑的单胺氧化酶抑制剂，以低剂量计划给予大鼠，使外周血对血浆HVA的贡献降低了42%至68%，导致62%至87%的血浆HVA来自大脑。使用该剂量计划，用碎片醌预处理的大鼠在较低剂量氟哌啶醇后显示出血浆HVA显著增加。在碎片醌预处理组中，脑HVA增加71%，血浆HVA显著增加60%，而载体预处理组需要脑HVA增加136%，血浆HVA显著增加50%。这些结果表明，碎片醌预处理提高了血浆HVA反映脑DA代谢变化的可靠性。从人体中获得的血浆HVA样本可能为评估神经和精神疾病的脑DA系统提供一种临床适用的方法。
Plasma levels of the dopamine (DA) metabolite homovanillic acid (HVA) may be a useful measure of brain HVA production by central DA systems. Even though there is a significant peripheral contribution to plasma HVA, experimental manipulations that alter brain HVA produce parallel changes in plasma HVA levels. This study was designed to assess whether the ability of plasma HVA to reflect haloperidol induced increases in brain HVA could be strengthened by reducing the contribution to plasma HVA from peripheral sources. Debrisoquin sulfate, a monoamine oxidase inhibitor that does not enter the brain, was given in a low dose schedule to rats and lowered the peripheral contribution to plasma HVA by between 42 and 68%, resulting in a situation where between 62 and 87% of plasma HVA derived from brain. Using this dose schedule, rats pretreated with debrisoquin displayed a significant increase in plasma HVA following a lower dose of haloperidol than that required in the vehicle pretreated rats. In the debrisoquin pretreated group, a 71% increase in brain HVA was accompanied by a significant 60% increase in plasma HVA, whereas the vehicle pretreated group required a 136% increase in brain HVA to display a significant 50% increase in plasma. These findings indicate that debrisoquin pretreatment improves the reliability of plasma HVA to reflect changes in brain DA metabolism. Plasma HVA samples obtained from humans following debrisoquin may provide a clinically applicable method for assessing brain DA systems in neurologic and psychiatric illness.